Why the Debate Over Gain-of-Function Moratoria Keeps Talking Past Itself

Every few years the biosecurity community arrives at roughly the same place: a high-profile incident, a congressional hearing, a flurry of agency guidance, and then a moratorium that satisfies almost no one. The cycle is not accidental. It reflects a genuine definitional problem that proponents of both stricter and looser oversight have largely declined to resolve.

The core dispute is not whether dangerous experiments should be regulated. Nearly everyone in the field agrees they should. The dispute is over what counts as gain-of-function research in the first place. The phrase was coined to describe work that confers new or enhanced capabilities on pathogens, but it has since been stretched to cover experiments that enhance transmissibility, lethality, host range, immune evasion, or some combination of those traits. Different agencies in different countries apply different definitions, and a single experiment can qualify under one framework while falling entirely outside another. That definitional slippage is not a bureaucratic inconvenience. It is the central structural weakness of any moratorium approach.

The case for periodic moratoria rests on a reasonable precautionary logic. Some experiments produce results whose risk profile cannot be fully anticipated before the work is done. A pause creates time for the oversight infrastructure to catch up with laboratory capability. The history of biosafety incidents at high-containment facilities, documented in open-source reporting from the Government Accountability Office and from biosafety journals, suggests that even well-resourced programs have consistent failure modes. A moratorium does not eliminate those failure modes but it reduces the probability that a failure coincides with a pathogen that has been deliberately enhanced.

The case against moratoria is also substantive. Blanket pauses tend to halt work that poses minimal risk while leaving the most consequential decisions in the hands of whoever writes the exemption criteria. Research on influenza receptor binding, on betacoronavirus spike protein function, on broadly neutralizing antibody targets - all of this sits in a gray zone where the same techniques that could produce a dangerous result can also produce a vaccine candidate. A moratorium that cannot distinguish between those two outcomes is not a precision instrument. It is a political signal dressed in technical language.

The deeper problem is governance, not science. The United States has attempted to address this through policy frameworks issued by the Department of Health and Human Services and through institutional review mechanisms, but those frameworks have undergone enough revision to indicate that consensus is not stable. Internationally, the Biological Weapons Convention lacks a formal verification mechanism, which means state-level compliance with any agreed norms is largely a matter of self-reporting. Assessing confidence on whether any major research power would honor a voluntary moratorium on strategically valuable pathogen work should be rated low.

What the moratorium debate tends to obscure is the question of what oversight architecture would actually work. Independent scientific review panels with biosecurity expertise and authority to delay or modify research, mandatory publication of dual-use review decisions, harmonized international definitions that have been stress-tested against real experimental designs - these proposals appear in the literature regularly and advance slowly. A moratorium, by contrast, is legible and announces quickly, which is why it gets traction even when its technical basis is contested.

The honest version of the case for moratoria acknowledges that they are buying time, not solving problems. The honest version of the case against them acknowledges that the oversight infrastructure that would make them unnecessary does not yet exist.